Triptan (English Wikipedia)

"Avanir's press release: FDA approves Onzetra". Avanir Pharmaceuticals. January 28, 2016. Archived from the original on May 11, 2016. Retrieved May 20, 2016.

bbc.co.uk

news.bbc.co.uk

"Pharmacies to sell migraine drug". BBC News. 2006-05-19. Archived from the original on 2006-09-24. Retrieved 2006-09-05.

books.google.com

Green, Mark W. (2015). "Overview of Migraine: Recognition, Diagnosis, and Pathophysiology". In Diamond, Seymour; Cady, Roger K.; Diamond, Merle L.; Green, Mark W.; Martin, Vincent T. (eds.). Headache and Migraine Biology and Management. Academic Press. p. 44. ISBN 978-0-12-800901-7. Archived from the original on 2018-05-06 – via GoogleBooks.

doi.org

Antonaci, Fabio; Ghiotto, Natascia; Wu, Shizheng; Pucci, Ennio; Costa, Alfredo (2016). "Recent advances in migraine therapy". SpringerPlus. 5: 637. doi:10.1186/s40064-016-2211-8. ISSN 2193-1801. PMC 4870579. PMID 27330903.
Brandes JL, Kudrow D, Stark SR, et al. (2007). "Sumatriptan-naproxen for acute treatment of migraine: a randomized trial". JAMA. 297 (13): 1443–1454. doi:10.1001/jama.297.13.1443. PMID 17405970.
Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M (2000). "Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study". Arch. Intern. Med. 160 (22): 3486–92. doi:10.1001/archinte.160.22.3486. PMID 11112243.
Sonal Sekhar, M.; Sasidharan, Shalini; Joseph, Siby; Kumar, Anand (January 1, 2012). "Migraine management: How do the adult and paediatric migraines differ?". Saudi Pharmaceutical Journal. 20 (1): 1–7. doi:10.1016/j.jsps.2011.07.001. ISSN 1319-0164. PMC 3745030. PMID 23960771.
Burstein, R; Collins, B; Jakubowski, M (2004). "Defeating migraine pain with triptans: A race against the development of cutaneous allodynia". Annals of Neurology. 55 (1): 19–26. doi:10.1002/ana.10786. PMID 14705108. S2CID 24040813.
Burstein, Rami; Jakubowski, Moshe; Rauch, Steven D. (2011). "The science of migraine". Journal of Vestibular Research: Equilibrium & Orientation. 21 (6): 305–314. doi:10.3233/VES-2012-0433. ISSN 0957-4271. PMC 3690498. PMID 22348935.
Eiland, L. S.; Hunt, M. O. (2010). "The use of triptans for pediatric migraines". Paediatr Drugs. 12 (6): 379–389. doi:10.2165/11532860-000000000-00000. PMID 21028917. S2CID 11187764.
Law, S; Derry, S; Moore, R. A. (2013). "Triptans for acute cluster headache". The Cochrane Database of Systematic Reviews. 7 (7): CD008042. doi:10.1002/14651858.CD008042.pub3. PMC 4170909. PMID 24353996.
Jafarian S, Gorouhi F, Salimi S, Lotfi J (2007). "Sumatriptan for prevention of acute mountain sickness: randomized clinical trial". Ann. Neurol. 62 (3): 273–7. doi:10.1002/ana.21162. PMID 17557349. S2CID 7799716.
Pierce, Mark; Marbury, Thomas; O'Neill, Carol; Siegel, Steven; Du, Wei; Sebree, Terri (2009-06-01). "Zelrix: a novel transdermal formulation of sumatriptan". Headache. 49 (6): 817–825. doi:10.1111/j.1526-4610.2009.01437.x. ISSN 1526-4610. PMID 19438727.
Gladstone, Jonathan (2003). "Newer formulations of the triptans: advances in migraine management". Drugs. 63 (21): 2285–2505. doi:10.2165/00003495-200363210-00002. PMID 14524731. S2CID 46971222 – via 2305.
Dodick, David W.; Shewale, Anand S.; Lipton, Richard B.; Baum, Seth J.; Marcus, Steven C.; Silberstein, Stephen D.; Pavlovic, Jelena M.; Bennett, Nathan L.; Young, William B.; Viswanathan, Hema N.; Doshi, Jalpa A.; Weintraub, Howard (January 2020). "Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data". Journal of Primary Care & Community Health. 11. doi:10.1177/2150132720963680. PMC 7585888. PMID 33095099.
Tepper, Stewart J.; Spears, Roderick C. (May 2009). "Acute Treatment of Migraine". Neurologic Clinics. 27 (2): 417–427. doi:10.1016/j.ncl.2008.11.008. PMID 19289223.
Ferrari, M. D.; Goadsby, P. J.; Roon, K. I.; Lipton, R. B. (2002). "Triptan (serotonin, 5-HT1D/1B agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials". Cephalalgia. 22 (8): 633–658. doi:10.1046/j.1468-2982.2002.00404.x. PMID 12383060. S2CID 2368571.
Gawde, Prathamesh; Shah, Harsh; Patel, Harsh; Bharathi, Koppineedi S; Patel, Neil; Sethi, Yashendra; Kaka, Nirja (2023). "Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium". Cureus. 15 (2): e34553. doi:10.7759/cureus.34553. ISSN 2168-8184. PMC 9985459. PMID 36879707.
Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D (2007). "Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability". Headache. 47 (8): 1152–68. doi:10.1111/j.1526-4610.2007.00849.x. PMID 17883520.
Dahlöf CG, Mathew N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245. S2CID 30125923.
Rolan, Paul E. (2012-09-25). "Drug Interactions with Triptans". CNS Drugs. 26 (11). Springer Science and Business Media LLC: 949–957. doi:10.1007/s40263-012-0002-5. ISSN 1172-7047. PMID 23018546. S2CID 43699741.
Shapiro, Robert E.; Tepper, Stewart J. (2007). "The Serotonin Syndrome, Triptans, and the Potential for Drug–Drug Interactions". Headache: The Journal of Head and Face Pain. 47 (2): 266–9. doi:10.1111/j.1526-4610.2006.00691.x. PMID 17300366. S2CID 21075435.
Evans, Randolph W.; Tepper, Stewart J.; Shapiro, Robert E.; Sun-Edelstein, Christina; Tietjen, Gretchen E. (2010). "The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper". Headache: The Journal of Head and Face Pain. 50 (6): 1089–99. doi:10.1111/j.1526-4610.2010.01691.x. PMID 20618823. S2CID 40713435.
Gillman (2010). "Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review". Headache. 50 (2): 264–272. doi:10.1111/j.1526-4610.2009.01575.x. PMID 19925619. S2CID 221752556.
Wenzel, R. G.; Tepper, S; Korab, W. E.; Freitag, F (2008). "Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?". Annals of Pharmacotherapy. 42 (11): 1692–6. doi:10.1345/aph.1L260. PMID 18957623. S2CID 24942783.
Orlova, Yulia; Rizzoli, Paul; Loder, Elizabeth (26 February 2018). "Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome". JAMA Neurology. 75 (5): 566–572. doi:10.1001/jamaneurol.2017.5144. PMC 5885255. PMID 29482205.
Tepper, S. J.; Rapoport, A. M.; Sheftell, F. D. (2002). "Mechanisms of action of the 5-HT1B/1D receptor agonists". Archives of Neurology. 59 (7): 1084–1088. doi:10.1001/archneur.59.7.1084. PMID 12117355.
Hamel, E. (1999). "The biology of serotonin receptors: focus on migraine pathophysiology and treatment". Can J Neurol Sci. 26 Suppl 3 (3). 26 Suppl 3:S2–6. doi:10.1017/s0317167100000123. PMID 10563226.
Lowther, S. (1992). "The distribution of 5HT_1D and 5HT_1E binding sites in human brain". Eur J Pharmacol. 222 (1): 137–42. doi:10.1016/0014-2999(92)90473-h. PMID 1468490.
Goadsby, P. J. (1998). "Serotonin 5HT_1B/1D receptor agonists in migraine - Comparative pharmacology and its therapeutic implications". CNS Drugs. 10 (4): 271–286. doi:10.2165/00023210-199810040-00005. S2CID 68150076.
Bigal, M. E.; Bordini, C. A.; Antoniazzi, A. L.; Speciali, J. G. (2003). "The triptan formulations: a critical evaluation". Arquivos de Neuro-Psiquiatria. 61 (2A): 313–320. doi:10.1590/s0004-282x2003000200032. PMID 12806521.
Armstrong, S. C.; Cozza, K. L. (2002). "Triptans". Psychosomatics. 43 (6): 502–504. doi:10.1176/appi.psy.43.6.502. PMID 12444236.
Mathew, N. T.; Loder, E. W. (2005). "Evaluating the triptans". The American Journal of Medicine Supplements. 118 (1): 28–35. doi:10.1016/j.amjmed.2005.01.017. PMID 15841885.
Deleu, D.; Hanssens Y. (2000). "Current and emerging second-generation triptans in acute migraine therapy: a comparative review". J Clin Pharmacol. 40 (7): 687–700. doi:10.1177/00912700022009431. PMID 10883409. S2CID 15585554.
Humphrey, P. P. (2007). "The discovery of a new drug class for the acute treatment of migraine". Headache. 47 (Suppl 1): S10–19. doi:10.1111/j.1526-4610.2007.00672.x. PMID 17425704. S2CID 12201740.

fda.gov

US Food and Drug Administration (2006-07-19). "Information for Healthcare Professionals". Food and Drug Administration. Archived from the original on 2008-02-19. Retrieved 2008-01-10.

gsksource.com

"Imitrex Nasal Spray package insert" (PDF). GlaxoSmithKline prescribing information. Archived (PDF) from the original on September 5, 2015. Retrieved May 20, 2016.

medicines.org.uk

emc.medicines.org.uk

"Relpax – 20 mg and 40 mg". Archived from the original on 2004-06-20. Retrieved 2008-11-09.

nih.gov

pubmed.ncbi.nlm.nih.gov

Antonaci, Fabio; Ghiotto, Natascia; Wu, Shizheng; Pucci, Ennio; Costa, Alfredo (2016). "Recent advances in migraine therapy". SpringerPlus. 5: 637. doi:10.1186/s40064-016-2211-8. ISSN 2193-1801. PMC 4870579. PMID 27330903.
Brandes JL, Kudrow D, Stark SR, et al. (2007). "Sumatriptan-naproxen for acute treatment of migraine: a randomized trial". JAMA. 297 (13): 1443–1454. doi:10.1001/jama.297.13.1443. PMID 17405970.
Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M (2000). "Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study". Arch. Intern. Med. 160 (22): 3486–92. doi:10.1001/archinte.160.22.3486. PMID 11112243.
Sonal Sekhar, M.; Sasidharan, Shalini; Joseph, Siby; Kumar, Anand (January 1, 2012). "Migraine management: How do the adult and paediatric migraines differ?". Saudi Pharmaceutical Journal. 20 (1): 1–7. doi:10.1016/j.jsps.2011.07.001. ISSN 1319-0164. PMC 3745030. PMID 23960771.
Burstein, R; Collins, B; Jakubowski, M (2004). "Defeating migraine pain with triptans: A race against the development of cutaneous allodynia". Annals of Neurology. 55 (1): 19–26. doi:10.1002/ana.10786. PMID 14705108. S2CID 24040813.
Burstein, Rami; Jakubowski, Moshe; Rauch, Steven D. (2011). "The science of migraine". Journal of Vestibular Research: Equilibrium & Orientation. 21 (6): 305–314. doi:10.3233/VES-2012-0433. ISSN 0957-4271. PMC 3690498. PMID 22348935.
Eiland, L. S.; Hunt, M. O. (2010). "The use of triptans for pediatric migraines". Paediatr Drugs. 12 (6): 379–389. doi:10.2165/11532860-000000000-00000. PMID 21028917. S2CID 11187764.
Kalra, A. A.; Elliott, D. (June 6, 2007). "Acute migraine: Current treatment and emerging therapies". Therapeutics and Clinical Risk Management. 3 (3): 449–459. ISSN 1176-6336. PMC 2386351. PMID 18488069.
Law, S; Derry, S; Moore, R. A. (2013). "Triptans for acute cluster headache". The Cochrane Database of Systematic Reviews. 7 (7): CD008042. doi:10.1002/14651858.CD008042.pub3. PMC 4170909. PMID 24353996.
Jafarian S, Gorouhi F, Salimi S, Lotfi J (2007). "Sumatriptan for prevention of acute mountain sickness: randomized clinical trial". Ann. Neurol. 62 (3): 273–7. doi:10.1002/ana.21162. PMID 17557349. S2CID 7799716.
Pierce, Mark; Marbury, Thomas; O'Neill, Carol; Siegel, Steven; Du, Wei; Sebree, Terri (2009-06-01). "Zelrix: a novel transdermal formulation of sumatriptan". Headache. 49 (6): 817–825. doi:10.1111/j.1526-4610.2009.01437.x. ISSN 1526-4610. PMID 19438727.
Gladstone, Jonathan (2003). "Newer formulations of the triptans: advances in migraine management". Drugs. 63 (21): 2285–2505. doi:10.2165/00003495-200363210-00002. PMID 14524731. S2CID 46971222 – via 2305.
Dodick, David W.; Shewale, Anand S.; Lipton, Richard B.; Baum, Seth J.; Marcus, Steven C.; Silberstein, Stephen D.; Pavlovic, Jelena M.; Bennett, Nathan L.; Young, William B.; Viswanathan, Hema N.; Doshi, Jalpa A.; Weintraub, Howard (January 2020). "Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data". Journal of Primary Care & Community Health. 11. doi:10.1177/2150132720963680. PMC 7585888. PMID 33095099.
Tepper, Stewart J.; Spears, Roderick C. (May 2009). "Acute Treatment of Migraine". Neurologic Clinics. 27 (2): 417–427. doi:10.1016/j.ncl.2008.11.008. PMID 19289223.
Ferrari, M. D.; Goadsby, P. J.; Roon, K. I.; Lipton, R. B. (2002). "Triptan (serotonin, 5-HT1D/1B agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials". Cephalalgia. 22 (8): 633–658. doi:10.1046/j.1468-2982.2002.00404.x. PMID 12383060. S2CID 2368571.
Gawde, Prathamesh; Shah, Harsh; Patel, Harsh; Bharathi, Koppineedi S; Patel, Neil; Sethi, Yashendra; Kaka, Nirja (2023). "Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium". Cureus. 15 (2): e34553. doi:10.7759/cureus.34553. ISSN 2168-8184. PMC 9985459. PMID 36879707.
Pascual J, Mateos V, Roig C, Sanchez-Del-Rio M, Jiménez D (2007). "Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability". Headache. 47 (8): 1152–68. doi:10.1111/j.1526-4610.2007.00849.x. PMID 17883520.
Dahlöf CG, Mathew N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245. S2CID 30125923.
Rolan, Paul E. (2012-09-25). "Drug Interactions with Triptans". CNS Drugs. 26 (11). Springer Science and Business Media LLC: 949–957. doi:10.1007/s40263-012-0002-5. ISSN 1172-7047. PMID 23018546. S2CID 43699741.
Shapiro, Robert E.; Tepper, Stewart J. (2007). "The Serotonin Syndrome, Triptans, and the Potential for Drug–Drug Interactions". Headache: The Journal of Head and Face Pain. 47 (2): 266–9. doi:10.1111/j.1526-4610.2006.00691.x. PMID 17300366. S2CID 21075435.
Evans, Randolph W.; Tepper, Stewart J.; Shapiro, Robert E.; Sun-Edelstein, Christina; Tietjen, Gretchen E. (2010). "The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper". Headache: The Journal of Head and Face Pain. 50 (6): 1089–99. doi:10.1111/j.1526-4610.2010.01691.x. PMID 20618823. S2CID 40713435.
Gillman (2010). "Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review". Headache. 50 (2): 264–272. doi:10.1111/j.1526-4610.2009.01575.x. PMID 19925619. S2CID 221752556.
Evans, R. W. (2007). "The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports". MedGenMed. 9 (3): 48. PMC 2100123. PMID 18092054.
Wenzel, R. G.; Tepper, S; Korab, W. E.; Freitag, F (2008). "Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?". Annals of Pharmacotherapy. 42 (11): 1692–6. doi:10.1345/aph.1L260. PMID 18957623. S2CID 24942783.
Orlova, Yulia; Rizzoli, Paul; Loder, Elizabeth (26 February 2018). "Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome". JAMA Neurology. 75 (5): 566–572. doi:10.1001/jamaneurol.2017.5144. PMC 5885255. PMID 29482205.
Tepper, S. J.; Rapoport, A. M.; Sheftell, F. D. (2002). "Mechanisms of action of the 5-HT1B/1D receptor agonists". Archives of Neurology. 59 (7): 1084–1088. doi:10.1001/archneur.59.7.1084. PMID 12117355.
Hamel, E. (1999). "The biology of serotonin receptors: focus on migraine pathophysiology and treatment". Can J Neurol Sci. 26 Suppl 3 (3). 26 Suppl 3:S2–6. doi:10.1017/s0317167100000123. PMID 10563226.
Lowther, S. (1992). "The distribution of 5HT_1D and 5HT_1E binding sites in human brain". Eur J Pharmacol. 222 (1): 137–42. doi:10.1016/0014-2999(92)90473-h. PMID 1468490.
Bigal, M. E.; Bordini, C. A.; Antoniazzi, A. L.; Speciali, J. G. (2003). "The triptan formulations: a critical evaluation". Arquivos de Neuro-Psiquiatria. 61 (2A): 313–320. doi:10.1590/s0004-282x2003000200032. PMID 12806521.
Armstrong, S. C.; Cozza, K. L. (2002). "Triptans". Psychosomatics. 43 (6): 502–504. doi:10.1176/appi.psy.43.6.502. PMID 12444236.
Mathew, N. T.; Loder, E. W. (2005). "Evaluating the triptans". The American Journal of Medicine Supplements. 118 (1): 28–35. doi:10.1016/j.amjmed.2005.01.017. PMID 15841885.
Deleu, D.; Hanssens Y. (2000). "Current and emerging second-generation triptans in acute migraine therapy: a comparative review". J Clin Pharmacol. 40 (7): 687–700. doi:10.1177/00912700022009431. PMID 10883409. S2CID 15585554.
Humphrey, P. P. (2007). "The discovery of a new drug class for the acute treatment of migraine". Headache. 47 (Suppl 1): S10–19. doi:10.1111/j.1526-4610.2007.00672.x. PMID 17425704. S2CID 12201740.

ncbi.nlm.nih.gov

Antonaci, Fabio; Ghiotto, Natascia; Wu, Shizheng; Pucci, Ennio; Costa, Alfredo (2016). "Recent advances in migraine therapy". SpringerPlus. 5: 637. doi:10.1186/s40064-016-2211-8. ISSN 2193-1801. PMC 4870579. PMID 27330903.
Sonal Sekhar, M.; Sasidharan, Shalini; Joseph, Siby; Kumar, Anand (January 1, 2012). "Migraine management: How do the adult and paediatric migraines differ?". Saudi Pharmaceutical Journal. 20 (1): 1–7. doi:10.1016/j.jsps.2011.07.001. ISSN 1319-0164. PMC 3745030. PMID 23960771.
Burstein, Rami; Jakubowski, Moshe; Rauch, Steven D. (2011). "The science of migraine". Journal of Vestibular Research: Equilibrium & Orientation. 21 (6): 305–314. doi:10.3233/VES-2012-0433. ISSN 0957-4271. PMC 3690498. PMID 22348935.
Kalra, A. A.; Elliott, D. (June 6, 2007). "Acute migraine: Current treatment and emerging therapies". Therapeutics and Clinical Risk Management. 3 (3): 449–459. ISSN 1176-6336. PMC 2386351. PMID 18488069.
Law, S; Derry, S; Moore, R. A. (2013). "Triptans for acute cluster headache". The Cochrane Database of Systematic Reviews. 7 (7): CD008042. doi:10.1002/14651858.CD008042.pub3. PMC 4170909. PMID 24353996.
Dodick, David W.; Shewale, Anand S.; Lipton, Richard B.; Baum, Seth J.; Marcus, Steven C.; Silberstein, Stephen D.; Pavlovic, Jelena M.; Bennett, Nathan L.; Young, William B.; Viswanathan, Hema N.; Doshi, Jalpa A.; Weintraub, Howard (January 2020). "Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data". Journal of Primary Care & Community Health. 11. doi:10.1177/2150132720963680. PMC 7585888. PMID 33095099.
Gawde, Prathamesh; Shah, Harsh; Patel, Harsh; Bharathi, Koppineedi S; Patel, Neil; Sethi, Yashendra; Kaka, Nirja (2023). "Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium". Cureus. 15 (2): e34553. doi:10.7759/cureus.34553. ISSN 2168-8184. PMC 9985459. PMID 36879707.
Evans, R. W. (2007). "The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports". MedGenMed. 9 (3): 48. PMC 2100123. PMID 18092054.
Orlova, Yulia; Rizzoli, Paul; Loder, Elizabeth (26 February 2018). "Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome". JAMA Neurology. 75 (5): 566–572. doi:10.1001/jamaneurol.2017.5144. PMC 5885255. PMID 29482205.

pharmacytimes.com

"Onzetra Xsail Approved as Migraine Treatment". pharmacytimes.com. February 3, 2016. Retrieved October 1, 2019.

semanticscholar.org

api.semanticscholar.org

Burstein, R; Collins, B; Jakubowski, M (2004). "Defeating migraine pain with triptans: A race against the development of cutaneous allodynia". Annals of Neurology. 55 (1): 19–26. doi:10.1002/ana.10786. PMID 14705108. S2CID 24040813.
Eiland, L. S.; Hunt, M. O. (2010). "The use of triptans for pediatric migraines". Paediatr Drugs. 12 (6): 379–389. doi:10.2165/11532860-000000000-00000. PMID 21028917. S2CID 11187764.
Jafarian S, Gorouhi F, Salimi S, Lotfi J (2007). "Sumatriptan for prevention of acute mountain sickness: randomized clinical trial". Ann. Neurol. 62 (3): 273–7. doi:10.1002/ana.21162. PMID 17557349. S2CID 7799716.
Gladstone, Jonathan (2003). "Newer formulations of the triptans: advances in migraine management". Drugs. 63 (21): 2285–2505. doi:10.2165/00003495-200363210-00002. PMID 14524731. S2CID 46971222 – via 2305.
Ferrari, M. D.; Goadsby, P. J.; Roon, K. I.; Lipton, R. B. (2002). "Triptan (serotonin, 5-HT1D/1B agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials". Cephalalgia. 22 (8): 633–658. doi:10.1046/j.1468-2982.2002.00404.x. PMID 12383060. S2CID 2368571.
Dahlöf CG, Mathew N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245. S2CID 30125923.
Rolan, Paul E. (2012-09-25). "Drug Interactions with Triptans". CNS Drugs. 26 (11). Springer Science and Business Media LLC: 949–957. doi:10.1007/s40263-012-0002-5. ISSN 1172-7047. PMID 23018546. S2CID 43699741.
Shapiro, Robert E.; Tepper, Stewart J. (2007). "The Serotonin Syndrome, Triptans, and the Potential for Drug–Drug Interactions". Headache: The Journal of Head and Face Pain. 47 (2): 266–9. doi:10.1111/j.1526-4610.2006.00691.x. PMID 17300366. S2CID 21075435.
Evans, Randolph W.; Tepper, Stewart J.; Shapiro, Robert E.; Sun-Edelstein, Christina; Tietjen, Gretchen E. (2010). "The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper". Headache: The Journal of Head and Face Pain. 50 (6): 1089–99. doi:10.1111/j.1526-4610.2010.01691.x. PMID 20618823. S2CID 40713435.
Gillman (2010). "Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review". Headache. 50 (2): 264–272. doi:10.1111/j.1526-4610.2009.01575.x. PMID 19925619. S2CID 221752556.
Wenzel, R. G.; Tepper, S; Korab, W. E.; Freitag, F (2008). "Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?". Annals of Pharmacotherapy. 42 (11): 1692–6. doi:10.1345/aph.1L260. PMID 18957623. S2CID 24942783.
Goadsby, P. J. (1998). "Serotonin 5HT_1B/1D receptor agonists in migraine - Comparative pharmacology and its therapeutic implications". CNS Drugs. 10 (4): 271–286. doi:10.2165/00023210-199810040-00005. S2CID 68150076.
Deleu, D.; Hanssens Y. (2000). "Current and emerging second-generation triptans in acute migraine therapy: a comparative review". J Clin Pharmacol. 40 (7): 687–700. doi:10.1177/00912700022009431. PMID 10883409. S2CID 15585554.
Humphrey, P. P. (2007). "The discovery of a new drug class for the acute treatment of migraine". Headache. 47 (Suppl 1): S10–19. doi:10.1111/j.1526-4610.2007.00672.x. PMID 17425704. S2CID 12201740.

web.archive.org

Green, Mark W. (2015). "Overview of Migraine: Recognition, Diagnosis, and Pathophysiology". In Diamond, Seymour; Cady, Roger K.; Diamond, Merle L.; Green, Mark W.; Martin, Vincent T. (eds.). Headache and Migraine Biology and Management. Academic Press. p. 44. ISBN 978-0-12-800901-7. Archived from the original on 2018-05-06 – via GoogleBooks.
"Imitrex Nasal Spray package insert" (PDF). GlaxoSmithKline prescribing information. Archived (PDF) from the original on September 5, 2015. Retrieved May 20, 2016.
"Zogenix, Inc. - Therapeutic Solutions for CNS Disorders and Rare Disease". www.zogenix.com. Archived from the original on 21 August 2016. Retrieved 6 May 2018.
US Food and Drug Administration (2006-07-19). "Information for Healthcare Professionals". Food and Drug Administration. Archived from the original on 2008-02-19. Retrieved 2008-01-10.
"AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig". www.astrazeneca.com. 7 June 2017. Archived from the original on 2018-03-22. Retrieved 2018-03-22.
"Relpax – 20 mg and 40 mg". Archived from the original on 2004-06-20. Retrieved 2008-11-09.
"Pharmacies to sell migraine drug". BBC News. 2006-05-19. Archived from the original on 2006-09-24. Retrieved 2006-09-05.
"Avanir's press release: FDA approves Onzetra". Avanir Pharmaceuticals. January 28, 2016. Archived from the original on May 11, 2016. Retrieved May 20, 2016.

worldcat.org

search.worldcat.org

Antonaci, Fabio; Ghiotto, Natascia; Wu, Shizheng; Pucci, Ennio; Costa, Alfredo (2016). "Recent advances in migraine therapy". SpringerPlus. 5: 637. doi:10.1186/s40064-016-2211-8. ISSN 2193-1801. PMC 4870579. PMID 27330903.
Sonal Sekhar, M.; Sasidharan, Shalini; Joseph, Siby; Kumar, Anand (January 1, 2012). "Migraine management: How do the adult and paediatric migraines differ?". Saudi Pharmaceutical Journal. 20 (1): 1–7. doi:10.1016/j.jsps.2011.07.001. ISSN 1319-0164. PMC 3745030. PMID 23960771.
Burstein, Rami; Jakubowski, Moshe; Rauch, Steven D. (2011). "The science of migraine". Journal of Vestibular Research: Equilibrium & Orientation. 21 (6): 305–314. doi:10.3233/VES-2012-0433. ISSN 0957-4271. PMC 3690498. PMID 22348935.
Kalra, A. A.; Elliott, D. (June 6, 2007). "Acute migraine: Current treatment and emerging therapies". Therapeutics and Clinical Risk Management. 3 (3): 449–459. ISSN 1176-6336. PMC 2386351. PMID 18488069.
Pierce, Mark; Marbury, Thomas; O'Neill, Carol; Siegel, Steven; Du, Wei; Sebree, Terri (2009-06-01). "Zelrix: a novel transdermal formulation of sumatriptan". Headache. 49 (6): 817–825. doi:10.1111/j.1526-4610.2009.01437.x. ISSN 1526-4610. PMID 19438727.
Gawde, Prathamesh; Shah, Harsh; Patel, Harsh; Bharathi, Koppineedi S; Patel, Neil; Sethi, Yashendra; Kaka, Nirja (2023). "Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium". Cureus. 15 (2): e34553. doi:10.7759/cureus.34553. ISSN 2168-8184. PMC 9985459. PMID 36879707.
Rolan, Paul E. (2012-09-25). "Drug Interactions with Triptans". CNS Drugs. 26 (11). Springer Science and Business Media LLC: 949–957. doi:10.1007/s40263-012-0002-5. ISSN 1172-7047. PMID 23018546. S2CID 43699741.

zogenix.com

"Zogenix, Inc. - Therapeutic Solutions for CNS Disorders and Rare Disease". www.zogenix.com. Archived from the original on 21 August 2016. Retrieved 6 May 2018.